How does 2MT0's PS Ratio compare to its peers?

2MT0 is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (14.6x).

How does 2MT0's PS Ratio compare vs other companies in the DE Biotechs Industry?

2MT0 is good value based on its Price-To-Sales Ratio (0.1x) compared to the European Biotechs industry average (8.1x).

What is 2MT0's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2MT0 is good value based on its Price-To-Sales Ratio (0.1x) compared to the estimated Fair Price-To-Sales Ratio (0.9x).

What is the Fair Price of 2MT0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate 2MT0's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Athenex (DB:2MT0) - Stock Price, News & Analysis

2MT0 Stock Overview

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. More details

2MT0 fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Trading at good value compared to peers and industry

Risk Analysis

Does not have a meaningful market cap (€10M)

Negative shareholders equity

Shareholders have been substantially diluted in the past year

Shares are highly illiquid

+ 2 more risks

Athenex, Inc. Competitors

co.don

XTRA:CNW

€6.5m

Medigene

XTRA:MDG1

€20.6m

Bellicum Pharmaceuticals

BST:BPXA

€772.4k

Heidelberg Pharma

XTRA:HPHA

€106.7m

Price History & Performance

Summary of all time highs, changes and price drops for Athenex
Historical stock prices
Current Share Price	US$3.27
52 Week High	US$22.77
52 Week Low	US$1.43
Beta	1.35
11 Month Change	0%
3 Month Change	-3.31%
1 Year Change	-65.09%
33 Year Change	-98.24%
5 Year Change	-98.85%
Change since IPO	-98.87%

Recent updates

Shareholder Returns

	2MT0	DE Biotechs	DE Market
7D	0%	0.8%	0.8%
1Y	-65.1%	-18.3%	8.6%

Return vs Industry: 2MT0 underperformed the German Biotechs industry which returned -23.1% over the past year.

Return vs Market: 2MT0 underperformed the German Market which returned 5.9% over the past year.

Price Volatility

Is 2MT0's price volatile compared to industry and market?
2MT0 volatility
2MT0 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 2MT0 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 2MT0's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2003	275	Johnson Lau	www.athenex.com

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through Oncology Innovation Platform and Commercial Platform segments. The company’s Orascovery product candidates include Oral paclitaxel and encequidar for the treatment of metastatic breast cancer.

Athenex, Inc. Fundamentals Summary

How do Athenex's earnings and revenue compare to its market cap?
2MT0 fundamental statistics
Market cap	€9.10m
Earnings (TTM)	-€90.28m
Revenue (TTM)	€94.74m

0.1x

P/S Ratio

-0.1x

P/E Ratio

Is 2MT0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2MT0 income statement (TTM)
Revenue	US$102.82m
Cost of Revenue	US$76.12m
Gross Profit	US$26.70m
Other Expenses	US$124.68m
Earnings	-US$97.98m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-11.31
Gross Margin	25.97%
Net Profit Margin	-95.29%
Debt/Equity Ratio	-511.7%

How did 2MT0 perform over the long term?

See historical performance and comparison

2MT0 Stock Overview

Rewards

Risk Analysis

Athenex, Inc. Competitors

XTRA:CNW

€6.5m

XTRA:MDG1

€20.6m

BST:BPXA

€772.4k

XTRA:HPHA

€106.7m

Price History & Performance

Recent News & Updates

Athenex, Inc. Announces the Separation of Joe Annoni as Assistant Chief Restructuring Officer

Nasdaq to Delist the Common Stock of Athenex

Athenex, Inc.(OTCPK:ATNX.Q) dropped from NASDAQ Composite Index

Athenex, Inc. announced delayed 10-Q filing

Nasdaq Staff Determines Athenex's Common Stock to be Delisted from Nasdaq as a Result of the Chapter 11 Case

Athenex, Inc.(NasdaqGS:ATNX) dropped from S&P TMI Index

Recent updates

Athenex, Inc. Announces the Separation of Joe Annoni as Assistant Chief Restructuring Officer

Nasdaq to Delist the Common Stock of Athenex

Athenex, Inc.(OTCPK:ATNX.Q) dropped from NASDAQ Composite Index

Athenex, Inc. announced delayed 10-Q filing

Nasdaq Staff Determines Athenex's Common Stock to be Delisted from Nasdaq as a Result of the Chapter 11 Case

Athenex, Inc.(NasdaqGS:ATNX) dropped from S&P TMI Index

Motion for Asset Sale Filed by Athenex, Inc.

Athenex Receives Letter from the Listing Qualifications Staff of the Nasdaq as the Company No Longer Meets Nasdaq Listing Rule 5450(b)(3)(C)

Athenex Announces Reverse Stock Split

Athenex Announces MHRA Decision on Oral Paclitaxel

Athenex, Inc. Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer

Insufficient new directors

Third quarter 2022 earnings released: US$0.14 loss per share (vs US$0.33 loss in 3Q 2021)

Athenex Announces Receipt of Positive Nasdaq Listing Determination

Athenex, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Athenex Receives Written Notification from Nasdaq Stating the Company Had Not Regained Compliance with the Rule and Was Ineligible to Obtain A Second 180 Calendar Day Period to Regain Compliance

Athenex, Inc. has completed a Follow-on Equity Offering in the amount of $29.995333 million.

Dr. Reddy's, Intas Reportedly in Talks to Buy Athenex

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.33 loss in 2Q 2021)

Athenex, Inc. to Report Q2, 2022 Results on Jul 28, 2022

TiHe Capital (Beijing) Co. Ltd. agreed to acquire Chongqing Taihao Pharmaceutical Co., Ltd. and Athenex Pharmaceuticals (Chongqing) Limited from Athenex, Inc. (NasdaqGS:ATNX) for CNY 124 million.

Athenex, Inc. Appoints Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy to Lead Its Clinical Development, Clinical Operations, and Regulatory Affairs Functions

Insufficient new directors

Athenex, Inc. Provides Sales Guidance for the Full Year 2022

First quarter 2022 earnings released: US$0.27 loss per share (vs US$0.27 loss in 1Q 2021)

Insufficient new directors

Athenex, Inc. to Report Q1, 2022 Results on May 10, 2022

Athenex Presents Interim Data from Phase 1 ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at the 2022 Transplantation & Cellular Meetings of ASTCT and CIBMTR

Kim Campbell Not to Stand for Re-Election to the Athenex Board of Directors At the 2022 Annual Meeting of Stockholders

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Athenex Announces Appoints Joe Annoni as Chief Financial Officer

ImmunityBio, Inc. (NasdaqGS:IBRX) completed the acquisition of Dunkirk Manufacturing Facility and Certain Related Assets of Athenex, Inc. (NasdaqGS:ATNX).

Athenex, Inc. Announces UK MHRA Validation of the Marketing Authorization Application for Oral Paclitaxel and Encequidar for Review

Athenex to Present Subgroup Analysis from Phase 3 Study of Oral Paclitaxel Plus Encequidar (KX-ORAX-001) in Metastatic Breast Cancer At SABCS 2021

Independent Director recently bought €54k worth of stock

Third quarter 2021 earnings released: US$0.33 loss per share (vs US$0.44 loss in 3Q 2020)

Independent Director recently bought €136k worth of stock

Chief Financial Officer Randoll Sze has left the company

Second quarter 2021 earnings released: US$0.33 loss per share (vs US$0.50 loss in 2Q 2020)

Athenex, Inc. Presents Data on Oral Docetaxel and Oral Paclitaxel at ASCO2021 Virtual Scientific Program

Athenex, Inc. Announces Klisyri® (Tirbanibulin) Receives Positive Chmp Opinion from the European Medicines Agency (Ema) for the Treatment of Actinic Keratosis of the Face or Scalp

Athenex, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine Present New Clinical Data on GD2 CAR-NKTCells in Neuroblastoma at ASGCT Annual Meeting

First quarter 2021 earnings released: US$0.27 loss per share (vs US$0.24 loss in 1Q 2020)

Athenex, Inc. Reaffirms Sales Guidance for the Year 2021

Athenex, Inc. (NasdaqGS:ATNX) acquired Kuur Therapeutics Limited.

Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against Athenex, Inc

Robbins LLP Reminds Shareholders that Athenex, Inc. is Being Sued for Misleading Shareholders

Insider recently sold €1.6m worth of stock

Independent Director recently sold €385k worth of stock

The Schall Law Firm Announces the Filing of A Class Action Lawsuit Against Athenex, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Athenex Receives FDA Complete Response Letter for Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer

Full year 2020 earnings released: US$1.72 loss per share (vs US$1.67 loss in FY 2019)

New 90-day low: €4.52

Revenue beats expectations

Athenex, Inc. to Report Q4, 2020 Results on Mar 01, 2021

Athenex, Inc. Enters into Second Amendment to the License Agreement

Athenex Announces New England Journal of Medicine Publication of Phase III Data on the Efficacy and Safety of Klisyri® (tirbanibulin)

New 90-day high: €11.80

Athenex Announces FDA Approval of Klisyri® (Tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp